• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Allies promote MRI-guided treatment

Article

Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused

Epix Medical and InSightec of Israel have allied to investigate the use of Epix's vascular MRI contrast agent, MS-325, to facilitate the treatment of tumors under MRI guidance. InSightec develops devices and software for MRI-guided high-intensity focused ultrasound, an investigational method of heating and destroying tumors or tissue such as uterine fibroids with millimeter precision. The collaboration will initially focus on preclinical studies leading to future use in the image-guided therapy program at Brigham and Women's Hospital in Boston. Epix and InSightec will share information on their technologies to optimize the use of contrast agents during interventional procedures.

© 2001 Miller Freeman Inc.
3/28/01, Issue # 1506, page 4.

Recent Videos
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.